SYDNEY, AUSTRALIA--(Marketwired - Jan 20, 2015) - Prima BioMed Ltd (
About Prima BioMed
Prima BioMed is a globally active biotech company developing immunotherapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value for its shareholders. Following the acquisition of Immutep SA, Prima owns a number of different immunotherapy products in preclinical and clinical development.
Contact Information:
For further information please contact:
Prima BioMed Ltd:
Stuart Roberts
+61 (0) 447 247 909
USA Investor/Media:
Adam Holdsworth
ProActive Capital
+1 (646) 862 4607
Australia Investor/Media:
Mr. Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505‐52